NGL Fine-Chem Limited (NGLFINE) fundamentals
NGL Fine-Chem Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as NGLFINE (ISIN INE887E01022). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What NGL Fine-Chem Limited does
NGL Fine-Chem Limited is an India-based company, which is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health. The Company caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen and others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets. It has manufacturing plants located around Mumbai.
Valuation and market data
| Last close | ₹2700.00 |
|---|---|
| Market capitalisation | ₹1,668 crore |
| Enterprise value | ₹1,732 crore |
| P/E (TTM) | 34.66 |
| Price to book | 5.07 |
| Price to sales (TTM) | 1.85 |
| Book value per share | ₹532.92 |
| Dividend yield | 6.48% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Jul 08 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹504 crore | ₹55 crore | ₹42 crore | 67.39 |
| Mar 2025 | ₹369 crore | ₹24 crore | ₹18 crore | 29.35 |
| Mar 2024 | ₹345 crore | ₹51 crore | ₹39 crore | 62.35 |
| Mar 2023 | ₹283 crore | ₹27 crore | ₹20 crore | 32.57 |
| Mar 2022 | ₹331 crore | ₹69 crore | ₹52 crore | 84.57 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 72.5% |
|---|---|
| Foreign institutions (FII) | 0.1% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 27.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.